文献速递肿瘤 PET/CT放射性药物与辐射防护

89Zr标记的纳武利尤单抗用于人源化小鼠肺癌模型T细胞浸润显像

89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-19

本研究合成89Zr-Df-纳武利尤单抗,在人源化A549肺癌小鼠模型中用PET显像PD-1阳性肿瘤浸润T细胞的体内分布。结果显示该示踪剂在体外和体内与刺激后表达PD-1的T细胞结合增高,PET可清晰勾勒皮下肿瘤及唾液腺、泪腺的T细胞浸润,组织学验证了PD-1表达,并据此估算人体剂量学。

要点

  • 89Zr-Df-纳武利尤单抗在体外和体内与刺激后表达PD-1的T细胞结合增高。
  • PET显像可清晰显示人源化A549荷瘤小鼠皮下肿瘤及唾液腺、泪腺的T细胞浸润。
  • 唾液腺和泪腺T细胞浸润经组织学分析确认,PD-1表达经免疫组化验证。

核心结论

  • 数据支持PD-1靶向药物可在体内实现肿瘤显像,可能有助于新型免疫治疗的设计与开发。
  • 未来免疫治疗生物标志物的无创显像可能有助于疾病诊断、疾病监测和患者分层。

研究设计与样本

  • 研究合成89Zr-Df-纳武利尤单抗,在人源化小鼠肺癌模型中用PET显像PD-1表达肿瘤浸润T细胞的体内分布。
  • 显像结果经离体生物分布研究验证,PD-1表达经免疫组化验证。
  • PET显像数据用于确定人体剂量学估算。

主要发现

  • 示踪剂在体外和体内与刺激后表达PD-1的T细胞结合增高。
  • 89Zr-Df-纳武利尤单抗PET显像通过靶向肿瘤和唾液腺中表达PD-1的局部活化T细胞,清晰勾勒出皮下肿瘤。
  • 除肿瘤摄取外,唾液腺和泪腺的T细胞浸润清晰可见,并经组织学分析确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nivolumab is a human monoclonal antibody specific for programmed cell death-1 (PD-1), a negative regulator of T-cell activation and response. Acting as an immune checkpoint inhibitor, nivolumab binds to PD-1 expressed on the surface of many immune cells and prevents ligation by its natural ligands. Nivolumab is only effective in a subset of patients, and there is limited evidence supporting its use for diagnostic, monitoring, or stratification purposes. METHODS: 89Zr-Df-nivolumab was synthesized to map the biodistribution of PD-1-expressing tumor infiltrating T-cells in vivo using a humanized murine model of lung cancer. The tracer was developed by radiolabeling the antibody with the positron emitter zirconium-89 (89Zr). Imaging results were validated by ex vivo biodistribution studies, and PD-1 expression was validated by immunohistochemistry. Data obtained from PET imaging were used to determine human dosimetry estimations. RESULTS: The tracer showed elevated binding to stimulated PD-1 expressing T-cells in vitro and in vivo. PET imaging of 89Zr-Df-nivolumab allowed for clear delineation of subcutaneous tumors through targeting of localized activated T-cells expressing PD-1 in the tumors and salivary glands of humanized A549 tumor-bearing mice. In addition to tumor uptake, salivary and lacrimal gland infiltration of T-cells was noticeably visible and confirmed via histological analysis. CONCLUSIONS: These data support our claim that PD-1-targeted agents allow for tumor imaging in vivo, which may assist in the design and development of new immunotherapies. In the future, noninvasive imaging of immunotherapy biomarkers may assist in disease diagnostics, disease monitoring, and patient stratification.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. England CG, Jiang D, Ehlerding EB, et al. 89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28821924. doi:10.1007/s00259-017-3803-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。